Simeprevir sodium

Simeprevir Sodium is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated in chronic hepatitis c virus infection. This drug has a black box warning from the FDA. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Sovriad and Olysio. Its PubChem CID is 46866715.

CAS No 1241946-89-3
Molecular Formula C38H46N5NaO7S2
Molecular Weight 771.9 g/mol
Synonyms sodium cyclopropylsulfonyl-[(1R,4R,6S,7Z,15R,17R)-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carbonyl]azanide

Frequently Asked Questions